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Background: Recent advances in time-lapse monitoring in IVF treatment have provided new morphokinetic
markers for embryonic competence. However, there is still very limited information about the relationship between
morphokinetic parameters, chromosomal compositions and implantation potential. Accordingly, this study aimed at
investigating the effects of selecting competent blastocysts for transfer by combining time-lapse monitoring and
array CGH testing on pregnancy and implantation outcomes for patients undergoing preimplantation genetic
screening (PGS).
Methods: A total of 1163 metaphase II (MII) oocytes were retrieved from 138 PGS patients at a mean age of 36.6 ±
2.4 years. These sibling MII oocytes were then randomized into two groups after ICSI: 1) Group A, oocytes (n = 582)
were cultured in the time-lapse system and 2) Group B, oocytes (n = 581) were cultured in the conventional incubator.
For both groups, whole genomic amplification and array CGH testing were performed after trophectoderm biopsy on
day 5. One to two euploid blastocysts within the most predictive morphokinetic parameters (Group A) or with the best
morphological grade available (Group B) were selected for transfer to individual patients on day 6. Ongoing
pregnancy and implantation rates were compared between the two groups.
Results: There were significant differences in clinical pregnancy rates between Group A and Group B (71.1% vs.
45.9%, respectively, p = 0.037). The observed implantation rate per embryo transfer significantly increased in Group
A compared to Group B (66.2% vs. 42.4%, respectively, p = 0.011). Moreover, a significant increase in ongoing
pregnancy rates was also observed in Group A compared to Group B (68.9% vs. 40.5%. respectively, p = 0.019).
However, there was no significant difference in miscarriage rate between the time-lapse system and the
conventional incubator (3.1% vs. 11.8%, respectively, p = 0.273).
Conclusions: This is the first prospective investigation using sibling oocytes to evaluate the efficiency of selecting
competent blastocysts for transfer by combining time-lapse monitoring and array CGH testing for PGS patients.
Our data clearly demonstrate that the combination of these two advanced technologies to select competent
blastocysts for transfer results in improved implantation and ongoing pregnancy rates for PGS patients.
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Since the inception of in vitro fertilization, selection of
the most competent embryos for transfer has been a
primary focus of investigation. As the field progressed,
an increasing number of studies have concentrated on
developing more advanced technologies, both invasive
and non-invasive, to select the most competent embryos
with the highest potential of implantation for transfer.
The original non-invasive technique, morphological grad-
ing has long been a primary method of evaluating and
selecting embryos for transfer [1-3]. Traditional pro-
cedures for embryo evaluation and selection are based
on the morphological characteristics observed with a
microscope at several discrete time points of embryonic
development. At the early cleavage stage, morphological
parameters including cell number, proportion of frag-
mentation, presence and number of nuclei, size and
symmetry of blastomeres are used to evaluate and select
embryos for transfer [1-9]. At the blastocyst stage, the
degree of blastocyst expansion and morphology of inner
cell mass (ICM) and trophectoderm (TE) are commonly
used to evaluate and grade the blastocysts [2,10]. Never-
theless, transfer of the top grade embryos often fails to
establish a viable pregnancy, while replacement of em-
bryos with poor morphological scores sometimes results
in a live birth. Thus, there are obvious shortcomings
with traditional methods of evaluation and selection of
embryos for transfer based on morphological character-
istics alone [11-14]. In addition, morphological evalu-
ation usually requires observation of embryos outside of
a conventional incubator. When embryos are evaluated
under a microscope in an uncontrolled environment,
they may suffer from undesirable shock or stress due to
sudden changes in known critical parameters including
temperature, oxygen concentration and pH [15-19].
The adverse effects associated with using conventional
incubators have limited the frequency of microscopic
evaluation of embryos, as only limited information about
growth and changes in embryonic morphology can be ob-
tained at a few discrete time points. The recent develop-
ment of time-lapse culture and monitoring has overcome
this limitation by combining incubation and observation
of embryos into one unique system [20-25]. As a result,
time-lapse monitoring has gradually emerged as one of
the most advanced non-invasive methods for evaluation of
embryonic competence [20-36]. A retrospective cohort
study with logistic regression analysis of a large sample
size (n = 7305) concluded that embryo incubation and
selection in the time-lapse system significantly improved
pregnancy and implantation rates compared to the con-
ventional incubator [34]. In contrast, other studies have
concluded that there were no significant differences in
clinical pregnancy outcomes between the time-lapse
system and the conventional incubator [32,33]. However,the chromosomal compositions of the transferred embryos
had not been determined when they were selected for
transfer to patients in any of these studies.
It has been well documented that the main cause of
embryo arrest, implantation failure and pregnancy loss is
the presence of numerical chromosome abnormality or
aneuploidy [11,37-43]. Aneuploidy is the most common
abnormality in in vitro fertilized embryos [44-46], and
increases with maternal age [39-41]. As the original inva-
sive method for embryo selection, preimplantation genetic
diagnosis (PGD) was initially applied to the screening of
X-linked disorders [47] and monogenetic diseases with
PCR [48,49], and later extended to aneuploidy screening
with the use of fluorescence in situ hybridization (FISH)
[50-53]. In early PGS studies, only a limited number of
chromosomes (5–12) were screened using FISH, which
had an error rate of 5-15% and resulted in disappointing
pregnancy outcomes [54-57]. Conventional CGH was then
introduced to screen all 24 chromosomes of oocytes and
embryos with some success [58-62]. Array CGH [63-71],
single nucleotide polymorphism (SNP) array [72-76] and
PCR-based comprehensive chromosomal screening (CCS)
[77-80] have been recently applied to the screening of em-
bryos before transfer to improve the efficiency of IVF and
PGD treatments. In these studies, polar body, blastomere
and/or trophectoderm biopsies were performed and cop-
ies of all 24 chromosomes were analyzed within 24–48
hours. However, the biopsied oocytes and embryos in
these studies were entirely cultured in the conventional in-
cubator and the impact of culture conditions on embryo
morphokinetics and implantation potential remains largely
unexplored, although some delay in blastocyst develop-
ment in vitro was observed following blastomere biopsy
on day 3 [31]. More recently, an interesting model for
classifying the risk of aneuploidy has been proposed based
on morphokinetics of human embryos that were cultured
in the time-lapse system [20]. However, pregnancy and
implantation data from the study group of patients were
unavailable in this report, although a retrospective study
was performed to apply this risk model to analyze the
outcomes of a group of IVF patients (without PGS)
whose embryos were monitored in the time-lapse sys-
tem [21]. To date, there is still very limited information
regarding the efficiency of combining time-lapse moni-
toring and array CGH testing to select competent blasto-
cysts for transfer in terms of pregnancy and implantation
outcomes.
At present, there is no consensus on the best way to
determine the competency of human embryos derived
from in vitro fertilization or to select the most compe-
tent embryos for transfer despite the recent advances in
both invasive and non-invasive techniques. In response
to this challenge, our current study explores the use of
both time-lapse monitoring and array CGH testing to
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improve pregnancy and implantation rates for PGS
patients. In particular, our approach for this study was
to compare the effects of the time-lapse system and the
conventional incubator on embryo ploidy and implant-




We obtained ethics approval for our study from the ethics
committees (also known as an Institutional Review Board,
IRB) at our respective institutions. All the participants had
the capacity to consent and we obtained written informed
consents from all patients enrolled in the current study.
Inclusion and exclusion criteria for patients
Patients undergoing preimplantation genetic screening
at our IVF clinics were offered enrollment in this IRB
approved study from February to December of 2012. A
written informed consent was obtained from all patients
and pre-treatment counseling was provided to each
couple. Standard clinical protocols and laboratory proce-
dures were used for the treatment of all patients in this
study. The cohort patients (n = 138) requested PGS with
array CGH screening due to the following clinical indica-
tions: 1) unexplained recurrent pregnancy loss (URPL):
patients (n = 71) with two or more unexplained miscar-
riages; 2) repeated implantation failure (RIF): patients
(n = 32) with implantation failure after three or more
IVF cycles or with transfer of 10 or more good morph-
ology embryos; and 3) previous aneuploid conceptions
(PAC): patients (n = 35) with one or more previous an-
euploid conceptions (e.g. Down Syndrome). Patients
were eligible for this study if they met the following in-
clusion criteria: 1) female patient’s age ≤ 39 years with
normal karyotypes; 2) ≥ 8 oocytes retrieved; 3) presence
of both ovaries and normal uterine lining; 4) undergoing
preimplantation genetic screening for their embryos; and
5) willingness to participate in the study and to follow in-
structions. PGS patients whose treatment incorporated
donor gametes or frozen and thawed embryos were not
included. Patients with severe endometriosis or endomet-
rial factors related infertility were excluded. Known trans-
location carriers (either parent) were also excluded from
this study.
Ovarian stimulation, oocyte retrieval and fertilization
All enrolled patients had an ultrasound scan and serum
evaluation of FSH, LH and E2 on day 2 of their menses
and were stimulated with conventional down-regulation
protocols. In brief, patients were down regulated with
Lupron and started stimulation on day 3 with r-FSH
(Gonal-F, Sereno). The patients were monitored withserial transvaginal ultrasound and E2 levels to monitor
their follicular growth and endometrial lining. When at
least three follicles reached ≥19 mm in diameter, a single
dosage of 250 μg recombinant hCG (Ovidrel, Sereno)
was administered. For all patients, oocyte retrieval was
performed under transvaginal ultrasound guidance at 35
to 36 hours after administration of hCG. After stripping
of cumulus cells, oocytes at MII stage were inseminated
with ICSI 4 hours after retrieval as previously described
[12,49]. The microinjected oocytes from each patient
were washed and pooled together in a culture dish con-
taining 1 mL modified human tubal fluid (mHTF, Irvine
Scientific, Irvine, USA) + 10% synthetic serum substitute
(SSS, Irvine Scientific, Irvine, USA). The microinjected
sibling oocytes were then randomized into two groups:
1) Group A: the microinjected oocytes were cultured in the
time-lapse system (EmbryoScope™, Unisense FertiliTech,
Aarhus, Denmark) at 37°C, 6% CO2, 5% O2; and 2) Group
B: the microinjected oocytes were cultured in the conven-
tional incubator (Heraeus, Heracell*, Thermo Scientific,
Waltham, MA, USA) at 37°C, 6% CO2, 20% O2. The con-
ventional incubator was used only for culture of the ran-
domized embryos throughout the entire study.
Embryo culture, trophectoderm biopsy and array CGH
analysis
For both groups, fertilization was assessed 16–18 hours
post insemination by ICSI. All zygotes with two pro-
nuclei and two polar bodies were considered normally
fertilized. All embryos in the two groups were cultured
from one-cell to blastocyst stage in a continuous single
culture medium (CSC, Irvine Scientific, Irvine, USA)
plus 10% SSS. For comparison, embryos in the two
groups were cultured in the same type of culture dish
(Embryoslide, Unisense FertiliTech, Denmark). Each well
of the culture dish was filled with 20 μl of the culture
medium and the slide was covered with 1.3 mL of light
mineral oil (Irvine Scientific, Irvine, USA). All culture
dishes were prepared and equilibrated at least 6 h prior
to use. When embryos developed to the blastocyst stage
on day 5, an opening of 6 to 9 um was made in the
zona pellucida with two to three pulses of 19 ms from
a non-contact 1.48 um diode Octax laser system (MTG,
Bruckberg, Germany), and an average of 4 (3 to 5) troph-
ectoderm (TE) cells were aspirated into a biopsy pipette
and separated from the blastocysts by applying several
laser pulses of 14 ms between the trophectoderm cells at
the stretching area. The biopsied TE cells were washed in
1x PBS and loaded into a PCR tube containing 2.5 μl 1x
PBS. All the biopsy and manipulation procedures were
performed in a fully enclosed isolator-based workstation
with temperature and gas control to provide a controlled
environment for manipulation of embryos (Origio Mid
Atlantic Devices, Mt. Laurel, USA).
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were performed as previously described [12-14]. In brief,
whole genomic amplification was performed using the
SurePlex kit (BlueGnome, Cambridge, UK). The ampli-
fied sample DNA and control (normal male and female)
DNA were labeled with Cy3 and Cy5 fluorophores for
2–4 hours. Labeled DNA was then re-suspended in a
dexsulphate hybridization buffer and hybridized onto
the 24 sure chips under cover slides for 4–6 hours. After
washing and drying, the hybridized 24 sure chips were
scanned at 10 μm using a laser scanner (Agilent, Sainte
Rosa, USA). The data was analyzed using the BlueFuse
Multi software (BlueGnome, Cambridge, UK) for whole
chromosome gain or loss.
Embryo evaluation and selection for transfer
In the conventional incubator group, fertilization was
assessed at 16 to 18 hours post ICSI under a stereo-
scope, and the fertilized zygotes were then cultured to
blastocyst stage as described above. Blastocysts were
evaluated microscopically and graded according to the
morphological criteria described elsewhere [10]. Blasto-
cysts were graded from 1 to 6 based on their degree of
expansion and hatching status: 1) Grade 1 or early
blastocyst: the blastocoele is less than half of the volume
of the embryo; 2) Grade 2 or blastocyst: the blastocoele
is more than half of the volume of the embryo; 3) Grade
3 or full blastocyst: the blastocoele occupies the embryos
completely; 4) Grade 4 or expanded blastocyst: the blas-
tocoele is larger than the early embryo and the zona pel-
lucida turns thinner; 5) Grade 5 or hatching blastocyst:
trophectoderm cells start herniating from the zona pel-
lucida; and 6) Grade 6 or hatched blastocyst: the blasto-
cyst has escaped the zona pellucida completely. For
blastocysts of Grades 3 to 6, inner cell mass (ICM) and
trophetoderm (TE) were also evaluated and graded ac-
cordingly. The ICM was graded into three categories: A
(many ICM cells packed together tightly), B (several
ICM cells grouped loosely) and C (very few ICM cells).
The trophectoderm was also graded into three categor-
ies: A (many trophectoderm cells forming a multiple
epithelium layer), B (few trophectoderm cells consisting
of a loose epithelium layer) and C (very few trophecto-
derm cells).
In the time-lapse system group, images of individual
embryos were captured with a built-in digital camera
every 20 minutes at 7 different focal planes. Fertilization
was assessed at 16 to 18 hours post ICSI insemination
according to the digital images acquired with the time-
lapse monitoring system. Detailed analysis of the acquired
images of each embryo was made with the EmbryoView
software (Unisense FertliTech, Denmark), and all the tar-
geted events related to embryonic development were then
annotated together with the corresponding hour post ICSIinsemination (hpi). All morphokinetic data were recorded
as mean ± SD hpi.
In the time-lapse system group, embryo selection for
transfer was primarily based on array CGH analysis.
When multiple euploid blastocysts were recognized from
individual patients, the morphokinetic markers were the
secondary criterion for selection according to the most
predictive parameters that are highly correlated with
implantation as described elsewhere [26,34]. The most
predictive parameters include (i) t5 = time of division to
5 cells: 48.8 - 56.6 hpi; (ii) cc2 = time between division
to 2 cells and division to 3 cells (≤11.9 h) and (iii) s2 =
time between division to 3 cells and subsequent division
to 4 cells (≤0.76 h). One to two euploid blastocysts
within the most predictive parameters were selected for
transfer to individual patients according to the patient’s
age and clinical indications on day 6. In the conventional
incubator group, embryo selection was primarily based
on the array CGH results. The morphological grading
by microscopic evaluation was the secondary criterion
for selection when multiple euploid blastocysts were
available. One to two euploid blastocysts with the best
morphological grade available were selected for transfer
to individual patients on day 6. The surplus euploid blas-
tocysts after embryo transfer in both groups were frozen
for future FET cycles as previously described [12-14].Sample size calculation and statistical analysis
Sample size was calculated using GraphPad StatMate
(GraphPad Software, San Diego, California, USA). Based
on our previous clinical studies in which nearly 50% of
all inseminated MII oocytes developed into blastocysts
[12-14], a sample size of 500 MII oocytes had an 80%
power to detect a difference between means of 0.20 with
a significance level of 0.05 (two-tailed value). Clinical
pregnancy, implantation and ongoing pregnancy rates
were tabulated and compared between the time-lapse
system and the conventional incubator groups. Clinical
pregnancy was defined as an intrauterine gestational sac
with fetal heartbeat visualized by ultrasound examination
at week 8 after embryo transfer. Ongoing pregnancy was
defined as continuing pregnancy at ≥ 20 weeks of gesta-
tion. Implantation rate was calculated as the total number
of sacs with fetal heart beat over total embryos transferred.
The categorical variables were analyzed by Chi-square
analysis or Fisher’s exact test as appropriate. The time-
lapse variables were first tested for normality using the
Shapiro-Wilk test first and then analyzed by the Mann–
Whitney test since the majority of the variables were nor-
mally distributed. The statistical analyses were performed
using GraphPad InStat version 3.10 (GraphPad Software,
San Diego, California, USA). A two-tailed value of p <0.05
was considered statistically significant.
Yang et al. BMC Medical Genomics 2014, 7:38 Page 5 of 13
http://www.biomedcentral.com/1755-8794/7/38Results
During the 10 month study period, a total of 138
(81.7%) patients who met all the inclusion criteria com-
pleted this study while 31 (18.3%) patients who had less
than 8 oocytes were excluded from this study. A total of
1163 metaphase II (MII) oocytes were retrieved from
138 PGS patients at a mean age of 36.6 ± 2.4 years. 126
(9.8%) of the retrieved oocytes at germinal vesicle (GV)
and/or metaphase I (MI) stages were excluded before
randomization. 1163 (90.2%) oocytes at metaphase II
(MII) stage were randomized into two groups after ICSI:
1) Group A, the microinjected oocytes (n = 582) were
cultured in the time-lapse system, and 2) Group B, the
microinjected oocytes (n = 581) were cultured in the
conventional incubator (Figure 1). There was no signifi-
cant difference in fertilization rate between Group A
and Group B (85.6% vs. 83.6%, respectively, p >0.05).
The blastocyst formation rate (per microinjected MII
oocytes) on day 5 in Group A was also similar to that
in Group B (48.9% vs. 47.8%, respectively, p >0.05)
(Table 1).
In the time-lapse system group, 263 (92.3%) blasto-
cysts were biopsied and analyzed by array CGH. Biopsies
could not be completed for 22 (7.7%) blastocysts due to
either poor morphology or degeneration after biopsy.











Figure 1 Schematic for oocytes randomized into either the time-lapse
GV = germinal vesicle; MI = metaphase I; MII = metaphase II; 2PN = two pr
oocytes in each group were circled in red. The total number of blastocystsand aneuploidy in 135 (51.3%) of the biopsied blasto-
cysts. No results occurred in 7 (2.7%) of the biopsied
blastocysts due to DNA amplification failure. In the con-
ventional incubator group, 265 (95.3%) blastocysts were
biopsied while 13 (4.7%) blastocysts were not biopsied
due to either poor morphology or degeneration after
biopsy. Array CGH analysis revealed euploidy in 105
(39.6%), aneuploidy in 156 (58.9%) and no results in 4
(1.5%) of the biopsied blastocysts (Table 2). There was
a non-significant trend towards more euploid embryos
developing to the blastocyst stage in the time-lapse
system group compared to the conventional incubator
group (46.0% vs. 39.6%, respectively, p >0.05). Chromo-
somal abnormalities were detected in all 24 chromosomes
in both Group A and Group B. All types of aneuploidies
were observed in both Group A and Group B, including
single chromosome gain (or trisomy), single chromosome
loss (or monosomy), dual (two) and complex (three or
more) chromosomal abnormalities (Figure 2). There were
no significant differences in the proportions of each type
of aneuploidy between the two groups (p >0.05) (Table 3).
The morphokinetic parameters of the early stages of em-
bryonic development were compared between euploid and
aneuploid embryos in the time-lapse monitoring group
(Figure 3). There were no significant differences in the













system (Group A) or the conventional incubator (Group B).
onuclei; Excluded immature (GV and MI) oocytes and unfertilized
associated with each group is circled in blue.
Table 1 Comparison of fertilization and blastocyst
formation rates between time-lapse system (Group A)
and conventional incubator (Group B)
Parameters Group A Group B p value
Total MII oocytes 582 581
Oocytes fertilized (2PN) 498 (85.6%) 486 (83.6%) 0.409a
Blastocysts 285 (48.9%) 278 (47.8%) 0.746a
MII = metaphase II; 2PN = two pronuclei; aby Chi-square analysis.
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respectively, p >0.05). The time between division to 2 cells
and division to 3 cells (cc2) of euploid embryos was simi-
lar to that of aneuploid embryos (11.2 ± 1.2 hpi vs. 11.3 ±
1.1 hpi, respectively, p >0.05). Moreover, the time between
division to 3 cells and subsequent division to 4 cells (s2)
was comparable between euploid and aneuploid embryos
(0.77 ± 0.69 hpi vs. 0.78 ± 0.71 hpi, respectively, p >0.05).
The morphokinetic parameters of the later stages of em-
bryonic development were also compared between euploid
and aneuploid embryos in the time-lapse monitoring
group (Figure 4). The time from insemination to initiation
of blastulation (tIB) was slightly delayed in aneuploid em-
bryos compared to euploid embryos (97.4 ± 6.5 vs. 96.1 ±
6.8 hpi, respectively, p >0.05). The time from insemination
to formation of a full blastocyst (tFB) of aneuploid em-
bryos was also marginally slower than that of euploid em-
bryos (104.3 ± 6.9 vs. 102.8 ± 7.2 hpi, respectively, p >0.05).
Additionally, the time from insemination to formation of
an expanded blastocyst (tEB) was comparable between an-
euploid and euploid embryos (110.9 ± 8.1 vs. 111.2 ± 7.6
hpi, respectively, p >0.05). Importantly, none of the differ-
ences in morphokinetic parameters between euploid and
aneuploid embryos approached statistical significance.
One to two euploid blastocysts within the most predict-
ive morphokinetic parameters (Group A) or with the best
morphological grade available (Group B) were selected for
transfer to individual patients. As shown in Table 4, a total
of 127 (92.0%) of the patients had euploid blastocysts for
transfer while 8 (5.8%) of the patients ended with no eu-
ploid embryos available for transfer. In addition, 3 (2.2%)
of the patients had embryos screened by array CGH
first and then had the euploid blastocysts cryopreservedTable 2 Comparison of biopsy and array CGH results
between time-lapse system (Group A) and conventional
incubator (Group B)
Parameters Group A Group B p value
Total blastocysts 285 278
Biopsied blastocysts 263 (92.3%) 265 (95.3%) 0.135a
No results 7 (2.7%) 4 (1.5%) 0.545b
Euploid 121 (46.0%) 105 (39.6%) 0.163a
Aneuploid 135 (51.3%) 156 (58.9%) 0.098a
aby Chi-square analysis, bby Fisher’s exact test.in order to avoid ovarian hyperstimulation syndrome
(OHSS). Among the patients with euploid blastocysts
for transfer in the time-lapse system group, 19 patients
had single euploid blastocysts and 26 patients had
double euploid blastocysts for transfer. In the conventional
incubator group, 15 patients had single euploid blastocyst
and 22 had double euploid blastocysts for transfer. The
remaining 45 patients chose to have mixed embryos (one
from the time-lapse system and one from the conventional
incubator) transferred because they had one euploid
blastocyst from each group available for transfer. These
patients had prior history of unexplained recurrent
pregnancy loss (n ≥ 2) and/or repeated implantation
failure (n ≥ 3), and preferred to transfer two euploid
blastocysts from both groups in order to increase the
chances of a successful pregnancy. There were signifi-
cant differences in clinical pregnancy rates between the
time-lapse system (Group A) and the conventional in-
cubator (Group B) (71.1% vs. 45.9%, respectively, p =
0.037). The observed implantation rate was significantly
higher in Group A compared to Group B (66.2% vs.
42.4%, respectively, p = 0.011). A significant difference in
ongoing pregnancy rate was also observed between Group
A and Group B (68.9% vs. 40.5%, respectively, p = 0.019).
However, there was no significant difference in miscar-
riage rate between Group A and Group B (3.1% vs. 11.8%,
respectively, p = 0.273).
As previously described, blastocysts were evaluated
and graded from 1 to 6 based on the morphological cri-
teria before selecting for transfer in both groups. The
morphological grades of transferred euploid blastocysts
were compared between the time–lapse system (Group A)
and the conventional incubator (Group B) (Table 5). There
was no significant difference in the percentage of each
morphological grade of the transferred euploid blastocysts
between the two groups (p >0.05). Data in Table 6 further
compare pregnancy and implantation outcomes between
the euploid blastocysts with early initiation of blastulation
(tIB < 96.1 hpi) and the euploid blastocysts with delayed
initiation of blastulation (tIB ≥ 96.1 hpi) in the time-lapse
system group. A non-significant increase in clinical preg-
nancy rate was observed in the euploid blastocysts with
early initiation of blastulation compared to the euploid
blastocysts with delayed initiation of blastulation (77.8%
vs. 61.1%, respectively, p >0.05). Moreover, there was
also an insignificant trend in which implantation rates
increased in the euploid blastocysts with early initiation
of blastulation compared to the euploid blastocysts with
delayed initiation of blastulation (71.4% vs. 58.6%, respect-
ively, p >0.05).
As shown in Table 7, there were a total of five miscar-
riages in five patients who had been clinically pregnant
with gestational sac(s) and fetal heart beat(s) after embryo
transfer: two in the conventional incubator (CI) group,
Chromosomal Position
Figure 2 (See legend on next page.)
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Figure 2 Representative array CGH profiles showing euploidy and different types of aneuploidy detected in both Group A and Group
B. I. Euploid profile with normal chromosomal copies; II. Aneuploid profile with single chromosomal gain (trisomy): a gain of chromosome 16; III.
Aneuploid profile with single chromosomal loss (monosomy): a loss of chromosome 6; IV. Aneuploid profile with dual chromosomal abnormalities:
losses of chromosomes 6 and 10; V. Aneuploid profile with complex chromosomal abnormalities: a gain of chromosome 19 and losses of
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mixed transfer (MIX) group. The average age of these pa-
tients was 38.2 years old (ranging from 37 to 39 years)
with the clinical indications of unknown recurrent preg-
nancy loss, repeated implantation failure or previous aneu-
ploid conceptions. Four of the patients (No. 2 to No. 5)
had their products of conception analyzed while patient
No. 1 had no cytogenetic analysis available due to an early
spontaneous abortion. Among patients with cytogenetic
analysis results, three patients (No. 2 to 4) had a singleton
pregnancy loss and the cytogenetic analysis of the prod-
ucts of conception revealed normal karyotypes for all three
patients. The leftover DNA samples from the blastocyst
biopsy were reanalyzed by array CGH which revealed the
same results as the cytogenetic analysis and the initial
array CGH diagnosis (euploid), indicating that there could
be a cause for the miscarriages other than aneuploidy in
these patients. One of the patients (No. 5) had twin preg-
nancy loss, and the follow-up cytogenetic analysis of the
products of conception revealed a mosaic 45X0/46XX and
a trisomy 16 miscarriage. Reanalysis of the leftover DNA
samples from the trophectoderm biopsy with array CGH
revealed the same results as the initial array CGH diag-
nosis (euploid), suggesting mosaicism as the cause for
the different results between the cytogenetic analysis (of
the products of conception) and the array CGH testing
(of the trophectoderm cells).
Discussion
The ultimate goal of preimplantation genetic screening
and assisted reproductive treatment is to select one to two
of the most competent embryos with normal chromosome
compositions for transfer in order to maximize the chances
of a successful pregnancy with delivery of a healthy babyTable 3 Comparison of array CGH results of aneuploid
blastocysts between time-lapse system (Group A) and
conventional incubator (Group B)
Parameters Group A Group B p value
Total aneuploid blastocysts 135 156
Monosomy 31 (22.9%) 34 (21.8%) 0.922a
Trisomy 22 (16.3%) 23 (14.7%) 0.839a
Dual chromosomal abnormality 36 (26.7%) 41 (26.3%) 0.941a
Complex (≥3) chromosomal
abnormality
46 (34.1%) 58 (37.2%) 0.668a
Monosomy = single chromosome loss; Trisomy = single chromosome gain;
aby Chi-square analysis.while minimizing the incidence of miscarriages in each
treatment cycle. Aneuploidy rates are extremely high in
IVF patients, especially in those with unexplained recur-
rent pregnancy loss [44], repeated implantation failure
[45] and/or previous aneuploid conceptions [46]. Recent
studies with array CGH screening have demonstrated a
significant improvement in pregnancy outcomes for PGS
patients [37,64-66]. Meanwhile, recent advances in time-
lapse culture and monitoring have provided new morpho-
kinetic markers for selecting competent embryos for
transfer [26,34]. In the current study, we have combined
these two advanced technologies available in our IVF
clinics to provide the advantage of selecting competent
blastocysts for transfer and thereby maximizing the
chances of a successful pregnancy for our PGS patients.
There were significant differences in clinical pregnancy
rates between the time-lapse system (Group A) and the
conventional incubator (Group B) (71.1% vs. 45.9%, re-
spectively, p = 0.037). Moreover, the implantation rate
was higher in Group A compared to Group B (66.2%
vs. 42.4%, respectively, p = 0.011). A significant differ-
ence in the ongoing pregnancy rate was also observed
between Group A and Group B (68.9% vs. 40.5%,0




Figure 3 Comparison of morphokinetic parameters of the early
stages of embryonic development between euploid and
aneuploid embryos in the time-lapse monitoring group.
t2 = time from insemination to 2 cells; t3 = time from insemination
to 3 cells; t5 = time from insemination to 5 cells; cc2 = time between
division to 2 cells and division to 3 cells; s2 = time between division
to 3 cells and subsequent division to 4 cells; hpi = hours post
insemination. Morphokinetic data were presented as mean ± SD.
There were no significant differences between euploid and
aneuploid embryos in each of the morphokinetic parameters





























Figure 4 Comparison of morphokinetic parameters of the later
stages of embryonic development between euploid and
aneuploid embryos in the time-lapse monitoring group.
t8 = time from insemination to 8 cells; tM = time from insemination
to formation of a compact morula; tIB = time from insemination to
initiation of blastulation; tFB = time from insemination to formation
of a full blastocyst. tEB = time from insemination to formation of a
expanded blastocyst. Morphokinetic data were presented as
mean ± SD. There were no significant differences between
euploid and aneuploid embryos in each of the morphokinetic
parameters (p >0.05 by Mann–Whitney test).
Table 5 Comparison of transferred euploid blastocysts at
each grade between time-lapse system (Group A) and
conventional incubator (Group B)
Parameters Group A Group B p value
Total transferred blastocysts 71 59
Transferred blastocysts at Grade 3 4 (5.6%) 5 (8.5%) 0.731a
Transferred blastocysts at Grade 4 26 (36.6%) 27 (45.7%) 0.381b
Transferred blastocysts at Grade 5 38 (53.5%) 26 (44.1%) 0.369b
Transferred blastocysts at Grade 6 3 (4.2%) 1 (1.7%) 0.625a
aby Fisher’s exact test, bby Chi-square analysis.
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distinct benefits of combining time-lapse monitoring
and array CGH testing to select competent blastocysts
for transfer for patients undergoing preimplantation
screening. A recent retrospective analysis of a large
number of IVF treatment cycles (n = 7305) also con-
cluded that monitoring and selecting embryos in the
time-lapse system significantly improved clinical preg-
nancy and implantation rates compared to the conven-
tional incubator [34].
Compared to previous reports, our current study has
multiple advantages with regard to studying the clinicalTable 4 Comparison of pregnancy and implantation
outcomes between time-lapse (Group A) and
conventional incubator (Group B), as well as the mixed
embryo transfer
Parameters Group A Group B Mixed p value
Patient with SET 19 15 n/a
Patient with DET 26 22 45
Clinical pregnancies after SET 10 5 n/a
Clinical pregnancies after DET 21 11 24
Clinical pregnancy rate 71.1% 45.9% 53.3% 0.037a
Implantation rate 66.2% 42.4% 47.8% 0.011a
Ongoing pregnancy rate 68.9% 40.5% 48.9% 0.019a
Pregnancy loss rate 3.1% 11.8% 8.3% 0.273b
SET = single embryo transfer; DET = double embryo transfer; Mixed =mixed
embryo transfer (one from the time-lapse system and one from the
conventional incubator); aGroup A vs. Group B, by Chi-square analysis; bGroup
A vs. Group B, by Fisher’s exact test.benefits of combining time-lapse monitoring and array
CGH testing to select competent blastocysts for transfer
in PGS patients. First, ploidy was determined with array
CGH testing, and selection of embryos for transfer was
primarily based on the array CGH results in both time-
lapse system and conventional incubator groups in order
to ensure that only euploid embryos were selected for
transfer to patients. In the time-lapse system group, the
morphokinetic markers within the most predictive pa-
rameters were the secondary criterion for selection when
multiple euploid blastocysts were recognized from indi-
vidual patients. In the conventional incubator group,
morphological grading by microscopic evaluation was
the secondary criterion for selection when multiple eu-
ploid blastocysts were available. However, in previous
studies comparing the time-lapse system and the con-
ventional incubator, ploidy of the transferred embryos
had not been determined before the embryos were se-
lected for transfer. Lack of chromosomal screening may
lead to transfer of euploid and/or aneuploid embryos to
patients, producing inconsistent data and conflicting preg-
nancy outcomes [32-34,36]. Second, in our prospective
study, a sibling oocyte model was designated so that the
patients served as their own control, and much larger
numbers of MII oocytes (n = 1163) were included in order
to draw a firmer statistical conclusion compared to the
earlier time-lapse studies with sibling oocytes [32,33].Table 6 Comparison of clinical pregnancy and
implantation rates between euploid blastocysts with
tIB < 96.1 hpi and euploid blastocysts with tIB ≥ 96.1 hpi
in Group A
Parameters tIB < 96.1 hpi tIB ≥ 96.1 hpi p value
Patient with SET 12 7
Patient with DET 15 11
Clinical pregnancies after SET 8 3
Clinical pregnancies after DET 13 8
Clinical pregnancy rate 77.8% 61.1% 0.383a
Implantation rate 71.4% 58.6% 0.386a
tIB = time from insemination to initiation of blastulation; hpi = hours post
insemination; SET = single embryo transfer; DET = double embryo transfer;
aGroup A vs. Group B, by Chi-square analysis.
Table 7 List of patients with pregnancy loss in time-lapse system (TL), conventional incubator (CI) and mixed transfer
(MIX) groups
Patient’s ID Age (years) Clinical indication Culture group Pregnancy loss Cytogenetic analysis Array CGH result
1 39 URPL CI Singleton Unknown Euploid
2 38 RIF CI Singleton 46XY Euploid
3 39 URPL TL Singleton 46XX Euploid
4 38 URPL MIX Singleton 46XY Euploid
5 37 PAC MIX Twin 47XX + 16, 45X0/46XX Euploid
URPL = unexplained recurrent pregnancy loss; RIF = repeated implantation failure; PAC = previous aneuploid conception; CI = conventional incubator;
TL = time-lapse system; MIX =mixed embryo transfer (one embryo from the time-lapse system and another one from the conventional incubator).
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patients (at a mean age of 36.6 ± 2.4 year ranging 28 to
39 years) was included in the present study in order to
avoid the effects of advanced maternal age on morpho-
kinetic parameters and chromosomal status of em-
bryos when compared to previous research exploring
the relationship between morphokinetic parameters
and aneuploidy [20]. It has been well documented that the
aneuploidy rate increases with maternal age [37-41,44-46],
especially at advanced maternal ages [11,70]. Recent stud-
ies have also revealed that maternal age is one of the major
confounding factors affecting clinical outcomes as related
to morphokinetic parameters of human embryos that were
cultured and monitored in time-lapse systems [34,36].
Furthermore, in the present study, the time-lapse system
was closely monitored and constantly operated with re-
duced oxygen tension (5%). In the previous studies com-
paring embryo culture in the time-lapse system and the
conventional incubator, however, embryos were entirely
cultured under atmospheric oxygen concentration (20%)
and the pregnancy and implantation outcomes were not
optimized in the time-lapse system group [32,33]. The sig-
nificance of culturing oocytes and embryos under low oxy-
gen tension has been well documented in mammalian
species including humans [16,18,81-83]. Studies with vari-
ous species of mammals have demonstrated that the con-
centration of oxygen inside the uterus and oviduct usually
falls in the ranges of 2-8%. Improved clinical pregnancy,
implantation and live birth rates have also been reported
after the use of reduced oxygen tension for embryonic
culture to the blastocyst stage [16,82,84]. These results
are associated with a reduction of the harmful effects of
reactive oxygen species (ROS). The increase in the gen-
eration and accumulation of ROS is associated with vari-
ous types of cell damage including DNA fragmentation,
altered gene expression, and organelle and membrane dis-
turbances in oocytes and embryos [81,82]. Consequently,
interrupted or delayed embryonic development, apoptosis
or health impairment during pregnancy can be observed in
embryos cultured under atmospheric conditions [83,84]. In
the current study, clinical pregnancy, implantation and
ongoing pregnancy rates were significantly improved in thetime-lapse system with reduced oxygen concentration
compared to the conventional incubator with atmospheric
oxygen concentration. Collectively, our data suggest that
the use of time-lapse culture and monitoring with low
oxygen tension may improve clinical and implantation
outcomes for PGS patients. Finally, the temperature was
strictly monitored and controlled in the time-lapse system
during the entire period of the current study. In addition,
all fertilized oocytes were cultured to the blastocyst stage
in the continuous single culture medium (CSC, Irvine
Scientific, Irvine, USA) to avoid sudden changes in culture
conditions, especially temperature fluctuation. Adverse
effects of temperature fluctuation on the meiotic spindle
have been well documented in various mammalian species
[18]. Transient cooling to room temperature can cause ir-
reversible disruption of the meiotic spindle in human oo-
cytes and embryos [19]. Such disruption may, in turn,
result in the elevated levels of aneuploidy in human oocyte
and embryos, especially when embryos are handled outside
of the incubator during medium change and evaluation,
where the earlier PGS studies were performed [53-57].
By combining these two advanced technologies, this
prospective study extends prior research where either
time-lapse monitoring or array CGH screening alone
was used for evaluation and selection of competent em-
bryos for transfer. To the best of our knowledge, this is
the first prospective study with sibling oocytes to apply
both time-lapse monitoring and array CGH testing to
select competent blastocysts for transfer in patients
undergoing preimplantation genetic screening. Our re-
search contributes new array CGH and time-lapse evalu-
ation data, assuring the importance of selecting competent
embryos for transfer in the PGS patients with various clin-
ical indications. The extent of aneuploidy in human em-
bryos can be extensive [37-46], although this rate is
typically lower in embryos at blastocyst stage [43,60]. This
prospective study provides further evidence of substantial
chromosomal abnormalities in apparently normal blasto-
cysts inside or outside of range of the most predictive
morphokinetic parameters, including monosomy, trisomy,
dual and complex aneuploidy [11,12,20,60]. Our data also
confirmed the previous observation that morphological
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of competent embryos for transfer [11,12]. Moreover,
there were no significant differences in any of the mor-
phokinetic parameters of the early embryonic develop-
ment between euploid and aneuploid embryos, although
there was a slight delay in some of the morphokinetic
parameters at the late stage of embryonic development
in aneuploid embryos compared to euploid embryos.
Additionally, there was a non-significant trend in which
clinical pregnancy and implantation rates increased in
the euploid blastocysts with early initiation of blastula-
tion compared to the euploid blastocysts with delayed
initiation of blastulation. These data suggest that ploidy
of the transferred blastocysts may be likely the primary
factor for determining the clinical pregnancy and im-
plantation outcomes in patients undergoing preimplan-
tation genetic screening, while morphokinetic markers
of the last stages of embryonic development (e.g. tIB)
may be used as a complementary system [20] to array
CGH for embryonic selection. Thus, the combination of
time-lapse monitoring and array CGH testing should be
recommended for PGS patients to maximize the chances
of successful pregnancies and to minimize the incidences
of harmful miscarriages.
Several limitations in our prospective study should be
addressed. First, although the combination of time-
lapse evaluation and array CGH screening displays dis-
tinct benefits for many patients undergoing preimplan-
tation genetic screening, this approach is not for all IVF
patients with various clinical indications, especially
those with diminished ovarian reserve or poor stimula-
tion responders. The improved implantation and on-
going pregnancy rates in the time-lapse monitoring
group noted here may not necessarily apply to patients
in all age groups, especially those over 40 years old. More-
over, the observed difference in results between array
CGH testing of the trophectoderm cells and the cytogen-
etic analysis of the products of conception suggests that
mosaicism may be the cause of the misdiagnosis of a small
proportion of human embryos at the blastocyst stages
[37,85], although this mosaicism rate is generally believed
to be lower than that of embryos at cleavage stages
[37,43,60,85]. Additionally, there was a non-significant
trend in which the rate of pregnancy loss decreased in the
time-lapse system compared to the conventional incubator
(3.1% vs. 11.8%, respectively, p = 0.273). This observation
may be due to the cumulative sample size being insuffi-
cient to detect a significant difference in this category. Fi-
nally, potential epigenetic effects as related to external
factors such as stimulation protocol, culture media, light
exposure, incubation conditions and manipulation of em-
bryos remain relatively unknown [86,87]. Further pro-
spective clinical trials with a larger scale of randomized
samples may be helpful in clarifying these issues.Conclusion
In conclusion, our results represent the first prospective
investigation using sibling oocytes to evaluate the effi-
ciency of selecting competent blastocysts for transfer by
combining time-lapse monitoring and array CGH testing
for patients undergoing preimplantation genetic screen-
ing. Our data clearly demonstrate that the combination
of these two advanced technologies to select competent
blastocysts for transfer results in improved implantation
and ongoing pregnancy rates for PGS patients. Further
randomized clinical trials with a larger sample size are
planned to verify these initial findings and to confirm
the clinical benefits of combining time-lapse monitoring
and array CGH testing for PGS patients.
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